BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19957161)

  • 1. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.
    Hsieh J; Longuet C; Baker CL; Qin B; Federico LM; Drucker DJ; Adeli K
    Diabetologia; 2010 Mar; 53(3):552-61. PubMed ID: 19957161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein.
    Hoffman S; Alvares D; Adeli K
    Mol Metab; 2022 Nov; 65():101590. PubMed ID: 36067913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
    Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
    J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice.
    Hsieh J; Trajcevski KE; Farr SL; Baker CL; Lake EJ; Taher J; Iqbal J; Hussain MM; Adeli K
    Endocrinology; 2015 Oct; 156(10):3538-47. PubMed ID: 26132919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
    Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Bahekar R; Jain M
    Biomed Pharmacother; 2018 Feb; 98():364-371. PubMed ID: 29275178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
    Hsieh J; Longuet C; Maida A; Bahrami J; Xu E; Baker CL; Brubaker PL; Drucker DJ; Adeli K
    Gastroenterology; 2009 Sep; 137(3):997-1005, 1005.e1-4. PubMed ID: 19482026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
    Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
    Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states.
    Hein GJ; Baker C; Hsieh J; Farr S; Adeli K
    Diabetes; 2013 Feb; 62(2):373-81. PubMed ID: 23028139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
    Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
    Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance.
    Taher J; Baker CL; Cuizon C; Masoudpour H; Zhang R; Farr S; Naples M; Bourdon C; Pausova Z; Adeli K
    Mol Metab; 2014 Dec; 3(9):823-33. PubMed ID: 25506548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice.
    Kooijman S; Wang Y; Parlevliet ET; Boon MR; Edelschaap D; Snaterse G; Pijl H; Romijn JA; Rensen PC
    Diabetologia; 2015 Nov; 58(11):2637-46. PubMed ID: 26254578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nobiletin Prevents High-Fat Diet-Induced Dysregulation of Intestinal Lipid Metabolism and Attenuates Postprandial Lipemia.
    Morrow NM; Trzaskalski NA; Hanson AA; Fadzeyeva E; Telford DE; Chhoker SS; Sutherland BG; Edwards JY; Huff MW; Mulvihill EE
    Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):127-144. PubMed ID: 34911361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
    Kang ZF; Deng Y; Zhou Y; Fan RR; Chan JC; Laybutt DR; Luzuriaga J; Xu G
    Diabetologia; 2013 Feb; 56(2):423-33. PubMed ID: 23188390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.
    Kedees MH; Guz Y; Grigoryan M; Teitelman G
    Peptides; 2013 Oct; 48():36-44. PubMed ID: 23927844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.